Jpmorgan Chase & CO Abeona Therapeutics Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Abeona Therapeutics Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 67,138 shares of ABEO stock, worth $382,686. This represents 0.0% of its overall portfolio holdings.
Number of Shares
67,138
Previous 38,532
74.24%
Holding current value
$382,686
Previous $163,000
160.12%
% of portfolio
0.0%
Previous 0.0%
Shares
7 transactions
Others Institutions Holding ABEO
# of Institutions
61Shares Held
26.9MCall Options Held
614KPut Options Held
45K-
Suvretta Capital Management, LLC New York, NY3.69MShares$21 Million0.92% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT3.43MShares$19.6 Million1.29% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.25MShares$18.5 Million0.04% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny2.3MShares$13.1 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.01MShares$11.4 Million0.0% of portfolio
About ABEONA THERAPEUTICS INC.
- Ticker ABEO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 5,950,380
- Market Cap $33.9M
- Description
- Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-a...